The Department of Health and Human Services, specifically the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC), are seeking proposals for Small Business Innovation Research (SBIR) contract proposals. The specific topic of the solicitation is "Point-of-Care Detection of Prostate Specific Antigen".
The technology being solicited is the development of an accurate and inexpensive home test for prostate-specific antigen (PSA). Prostate cancer is a significant cause of cancer mortality, and PSA screening has been shown to reduce mortality rates. However, after a recommendation against screening in 2012, the mortality curve flattened and the incidence of metastatic disease increased. Therefore, the development of a home test for PSA has the potential to increase the detection of disease amenable to curative therapy or surveillance, particularly among high-risk populations such as African American men.
The solicitation is open to Fast-Track proposals and will not accept Direct-to-Phase II proposals. The anticipated number of awards is 3-5, and the budget for Phase I is up to $400,000 for up to 12 months, while Phase II is up to $2,000,000 for up to 2 years. Proposals that exceed the budget or project duration may not be funded.
This topic aligns with the Cancer Moonshot Blue Ribbon Panel recommendation to expand the use of proven cancer prevention and early detection strategies. The solicitation is closed, and more information can be found on the grants.gov website.